Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. is the next best biotech stock on our list.

TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target. The firm said the upcoming VIKTORIA-1 trial readout for Celcuity’s gedatolisib could act as a positive catalyst for mutant-selective inhibitors such as RLAY’s zovegalisib. Oppenheimer expects the VIKTORIA-1 results to fall short of expectations. He noted that anything below a “teenage” median progression-free survival for the gedatolisib triplet would establish a competitive benchmark that RLAY’s zovegalisib-based regimen could surpass.

Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors

Regarding Zovegalisib, Relay Therapeutics, Inc. presented a subset of results from interim clinical data for the drug at the 2025 San Antonio Breast Cancer Symposium on December 12, 2025. Zovegalisib and fulvestrant together produced a median progression-free survival of 11.4 months in second-line patients in the ReDiscover first-in-human trial. Despite substantial prior treatment, efficacy was consistent across several patient subgroups.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company using advanced computational and experimental technologies to accelerate drug discovery. Its Dynamo platform targets previously intractable protein targets to develop small-molecule therapies, primarily in precision oncology and genetic diseases.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.